Mark Edinger, Victor Wegman, Patrick Hurban, Alan Wookey, Franklin Sedarat, and Patrice Hugo, Q2 Solutions
Minimal residual disease (MRD) as a predictor of outcomes
Measurement of residual disease is one of the most reliable predictors of treatment outcome for leukemia and lymphoma, and in many cases the most reliable. Although initially found to be of great value in monitoring Chronic Myelogenous Leukemia (CML), it has become generally useful across other types of leukemia, lymphoma and myeloma.1 It has become an essential tool for monitoring, modifying and reinitiating therapeutic intervention. Key considerations for elucidating the right tool for MRD detection include:
- Requirements for sample input
- Cell numbers
- Number of phenotypic markers to deliver highest level of detection (i.e. best sensitivity)
- Cutoff value for detection
There are multiple measurement approaches for MRD testing and key criteria to consider when selecting the right tool for MRD detection.
Download this insight brief to discover what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.